Resources

Brainomix is set to launch its new Brainomix 360 Next Generation platform at the International Stroke Conference (ISC).

What an incredible night! Last Thursday, we welcomed a record 780 of you to the Roundhouse for the 2026 BIA Gala Dinner. It was a powerful reminder of the strength, resilience and sheer brilliance of our community.

In this blog, Saqib Lal, Head of Content at BIA, reflects on a stellar Gala Dinner. He describes it as a moment to pause and recognise the extraordinary people who make the UK life sciences sector a global powerhouse. This year, as a record 780 guests gathered at the iconic Roundhouse for an evening that demonstrated renewed ambition and positivity. 

Coulter Partners successfully led a search assignment for Kaffe Bueno and is pleased to announce the placement of Thomas Durhuus as Chief Executive Officer (CEO).

In this blog, Emily Klein, Senior Policy and Public Affairs Executive at BIA, explores the hidden, wide-ranging impacts and costs of rare diseases to society and the wider economy in the UK.

Fleet Bioprocessing Ltd has announced the launch of a new contract development service for Lateral Flow Devices (LFDs), expanding its capabilities in response to strong growth in point-of-care and decentralised diagnostics.

The BioIndustry Association (BIA) has recognised the achievements of Dr Ruth McKernan CBE, neuroscientist, entrepreneur, investor and former Chair of the BIA Board, with the inaugural Chiswell Lifetime Achievement Award.

Complement Therapeutics GmbH (CTx) has received Clinical Trial Authorisation (CTA) approval in the United Kingdom for CTx001.

Collaboration to Deliver High-Quality Cytokines and Growth Factors to Enable the Advancement of Stem Cell-Based Therapeutics

Poolbeg Pharma (AIM: POLB), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces the publication of a peer-reviewed paper from the POLB 001 LPS human challenge trial in Frontiers in Immunology.

PIR International recently partnered with Dynamic42 in appointing Wolfgang Kintzel as Executive Chair

Professor Cathy Tralau-Stewart, Executive Director of the Milner Therapeutics Institute, has continued her thought leadership work with an article in Drug Discovery World.

Scancell Holdings plc, the developer of active immunotherapies to treat cancer, announces the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for a registrational Phase 3 trial of its iSCIB1+ Immunobody® in advanced melanoma, with progression free survival as the agreed surrogate endpoint.

As 2026 shapes up to an unpredictable year, our policy experts have provided more grounding for what the life sciences sector should expect over the next 12 months. This is the second and final part of our 2026 outlook series. 

Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully led a search assignment for TreeFrog Therapeutics and is pleased to announce the placement of Mark Rothera as Chief Executive Officer (CEO).

Stablepharma will apply its proprietary stabilisation technology, initially focused on vaccines, to non-vaccine sterile injectables that currently require cold-chain storage. Stablepharma will be eligible to receive future milestone and royalty revenue from AFT upon commercialisation.

UK biotech has demonstrated resilience in a challenging 2025 and enters 2026 with renewed confidence and broadening investor appetite, the BioIndustry Association’s (BIA) report UK biotech financing 2025 has found.

Our UK biotech financing 2025 report is out today, including data and commentary on how the biotech investment landscape fared last year. 2025 was a brutal year for the sector, but an upswing in deal numbers going into 2026 and recent capital injections give good reason to be optimistic.